1.
Gupta P, Leroux C, Patterson BK, et al. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen. J Infect Dis 2000 ; 182 : 79-87.
2.
Le Tortorec A, Dejucq-Rainsford N. HIV infection of the male genital tract - consequences for sexual transmission and reproduction. Int J Androl 2009 ; 32 : 1-12.
3.
Paranjpe S, Craigo J, Patterson B, et al. Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retrovir 2002 ; 18 : 1271-80.
4.
Ghosn J, Viard JP, Katlama C, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004 ; 18 : 447-57.
5.
Dejucq N, Jegou B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 2001 ; 65 : 208-31.
6.
Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007 ; 131 : 1059-71.
7.
Maher D, Wu X, Schacker T, et al. HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci USA 2005 ; 102 : 11504-9.
8.
Roan NR, Sowinski S, Munch J, et al. Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem 2010 ; 285 : 1861-9.
9.
Sabatte J, Ceballos A, Raiden S, et al. Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN. J Virol 2007 ; 81 : 13723-34.
10.
Martellini JA, Cole AL, Venkataraman N, et al. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J 2009 ; 23 : 3609-18.
11.
Cherrier T, Le Douce V, Redel L, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Partie II : la réactivation de la latence du VIH-1 et ses implications thérapeutiques. Med Sci (Paris) 2010 ; 26 : 291-5.
12.
Schwartz C, Le Douce V, Cherrier T, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Partie I : la physiologie de la latence du VIH-1. Med Sci (Paris) 2010 ; 26 : 159-63
13.
Estaquier J, Hurtrel B. Sanctuaire du virus de l’immunodéficience humaine et mécanismes d’échappement. Med Sci (Paris) 2008 ; 24 : 1055-60.
14.
Cherrier T, Le Douce V, Redel L, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Partie II : la réactivation de la latence du VIH-1 et ses implications thérapeutiques. Med Sci (Paris) 2010 ; 26 : 291-6.
15.
Leruez-Ville M, Dulioust E, Costabliola D, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002 ; 16 : 486-8.
16.
Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009 ; 23 : 2050-4.
17.
Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008 ; 22 : 1677-9.
18.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai project study group. N Engl J Med 2000 ; 342 : 921-9.
19.
Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009 ; 23 : 1397-404.
20.
Sturmer M, Doerr HW, Berger A, Gute P. Is transmission of HIV-1 in nonviraemic serodiscordant couples possible? Antivir Ther 2008 ; 13 : 729-32.
21.
Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008 ; 372 : 314-20.
22.
Legeai C, Auvert B. La circoncision : un espoir de réduction de l’infection à VIH en Afrique australe. Med Sci (Paris) 2008 ; 24 : 499-504.
23.
Bujan L, Hollander L, Coudert M, et al. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network. AIDS 2007 ; 21 : 1909-14.
24.
Dulioust E, Du AL, Costagliola D, et al. Semen alterations in HIV-1 infected men. Hum Reprod 2002 ; 17 : 2112-8.
25.
Bujan L, Sergerie M, Moinard N, et al. Decreased semen volume and spermatozoa motility in HIV-1 infected patients under antiretroviral treatment. J Androl 2007 ; 28 : 444-52.
26.
van Leeuwen E, Wit FW, Repping S, et al. Effects of antiretroviral therapy on semen quality. AIDS 2008 ; 22 : 637-42.
27.
Dussaix E, Guetard D, Dauguet C, et al. Spermatozoa as potential carriers of HIV. Res Virol 1993 ; 144 : 487-95.
28.
Ceballos A, Remes Lenicov F, Sabatte J, et al. Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J Exp Med 2009 ; 206 : 2717-33.
29.
Muciaccia B, Corallini S, Vicini E, et al. HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Hum Reprod 2007 ; 22 : 2868-78.
30.
Roulet V, Denis H, Staub C, et al. Human testis in organotypic culture: application for basic or clinical research. Hum Reprod 2006 ; 21 : 1564-75.
31.
Roulet V, Satie AP, Ruffault A, et al. Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol 2006 ; 169 : 2094-103.
32.
Le Tortorec A, Le Grand R, Denis H, et al. Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One 2008 ; 3 : e1792.
33.
Shehu-Xhilaga M, Kent S, Batten J, et al. The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the postacute stage of infection. Retrovirology 2007 ; 4 : 7.
34.
Muciaccia B, Filippini A, Ziparo E, et al. Testicular germ cells of HIV- seropositive asymptomatic men are infected by the virus. J Reprod Immunol 1998 ; 41 : 81-93.
35.
Smith DM, Kingery JD, Wong JK, et al. The prostate as a reservoir for HIV-1. AIDS 2004 ; 18 : 1600-2.
36.
Le Tortorec A, Satie AP, Denis H, et al. Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. Retrovirology 2008 ; 5 : 119.
37.
Kiessling AA, Fitzgerald LM, Zhang D, et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retrovir 1998 ; 14 : S33-41.
38.
Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999 ; 28 : 1252-9.
39.
Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998 ; 339 : 1803-9.
40.
Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV cohort study. Aids 2000 ; 14 : 117-21.
41.
Gunthard HF, Havlir DV, Fiscus S, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001 ; 183 : 1318-27.
42.
Lafeuillade A, Solas C, Halfon P, et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002 ; 3 : 27-35.
43.
Solas C, Lafeuillade A, Halfon P, et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003 ; 47 : 238-43.
44.
Bujan L, Daudin M, Matsuda T, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. Aids 2004 ; 18 : 757-66.
45.
Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial. Aids 2007 ; 21 : 1309-15.
46.
Pasquier CJ, Moinard N, Saune K, et al. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. Aids 2008 ; 22 : 1894-6.
47.
Nunnari G, Otero M, Dornadula G, et al. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. Aids 2002 ; 16 : 39-45.
48.
Craigo JK, Patterson BK, Paranjpe S, et al. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res Hum Retrovir 2004 ; 20 : 1196-209.